阿那莫林(Adlumiz)说明书,作用功效,用法用量,副作用,禁忌症？

According to 2014 European ESMO news reports, taking into account effective medical needs, new drugs are expected to be the first to effectively improve

Treatment options for patients with cancer anorexia and cachexia. The following is a detailed explanation of Anamorelin (Adlumiz) instructions, effects, usage and dosage, side effects, and contraindications.

Indications for Anamorelin (Adlumiz)

Anamorelin (Adlumiz) is used to treat cachectic patients with unresectable advanced and recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer who have poor response to nutritional therapy and other cancer cachexia patients who have lost more than 5% of their body weight within 3.6 months and have loss of appetite, and who meet more than 2 of the following 1-3. It can be used:

1. Feeling of fatigue or burnout;

2. Reduction of body muscles and bones;

3. The CRP value exceeds 0.5mg/dl, the hemoglobin value is less than 12g/dl or the albumin value is less than 3.2g/dl.

Anamorelin (Adlumiz) usage and dosage

1. Dosage and management

The usual oral dose for adults is 100 mg of anamorelin hydrochloride once daily on an empty stomach.

2. Precautions related to dosage and medication

(1) To avoid the influence of food, the medicine should be taken on an empty stomach and no food should be eaten within one hour after taking the medicine.

(2) If your weight does not increase or your appetite does not improve after taking the medicine, in principle, you should stop taking the medicine after 3 weeks.

(3) There is currently no experience in continuous medication for more than 12 weeks. Whether you need to continue taking medication should be checked regularly, such as through interviews to check weight and appetite.

The role of Anamorelin (Adlumiz)

Anamorelin is a growth hormone-releasing drug that increases appetite and promotes weight gain. It is mainly used to treat cancer patients and the elderly who suffer from malnutrition and wasting caused by disease, medical procedures or chemotherapy. Anamorelin can promote the secretion of growth hormone (GH) by stimulating the secretion of growth hormone-releasing hormone (GHRH) from the anterior pituitary gland. Growth hormone is a hormone that stimulates protein synthesis, prevents muscle breakdown, and promotes fat breakdown. By increasing appetite and promoting weight gain, anamorelin can improve patients' physical condition and quality of life.

Anamorelin (Adlumiz) Efficacy

According to the results, 49 patients with cachexia suffering from digestive cancer (colorectal cancer, gastric cancer, pancreatic cancer) were treated with anamorelin (Adlumiz) for 12 weeks, and a significant appetite-increasing effect was observed in 63.3% (31 cases) of the patients. Within 3 weeks of taking the drug, the patient gained weight, which continued through 12 weeks. After the first week of taking it, patients' appetite improved and more patients found food more palatable. The researchers said their personal impression in clinical trials was that patients' appetites increased within days of starting the drug. For patients with early cachexia, anamorelin will be effective starting from the day of administration.

After 3 weeks of taking the drug, an evaluation will be carried out, and if no weight gain or improvement in appetite is observed by that time, the drug will in principle be discontinued. In addition, since patients were only given the drug for 12 weeks in the clinical trial, doctors should carefully consider whether to continue using the drug based on data such as weight and appetite improvement if it exceeds 12 weeks.

Anamorelin (Adlumiz) is a cancer cachexia treatment drug and a supportive medical drug for cancer treatment. Similar to using antiemetics to reduce the side effects of nausea and vomiting in patients.

Anamorelin (Adlumiz) Side Effects

One of the major side effects of anamorelin (Adlumiz) is an increase in serum gamma-glutamyl transpeptidase (γ-GTP), and another side effect is an increase in glycated hemoglobin. These side effects may occur while using anamorelin, but not everyone will experience it.

Serum gamma-glutamyl transpeptidase (γ-GTP) is an enzyme whose elevation may be related to liver function. If an increase in γ-GTP occurs during use of anamorelin, the following treatments may be considered:

1. Regularly detect blood indicators: monitor changes in γ-GTP levels to detect any abnormalities in time.

2. Consult with a doctor: If γ-GTP increases significantly or continues to increase, you should contact the attending doctor in time to understand further evaluation and treatment methods.

Increases in glycosylated hemoglobin may be related to glycemic control. If an increase in glycated hemoglobin occurs while taking anamorelin, the following management measures may be considered:

1. Adjust diet and medication: Follow the advice of your doctor or nutritionist and adjust your diet and medication to control blood sugar levels.

2. Monitor blood sugar regularly: Check blood sugar levels regularly so that treatment plans can be adjusted in a timely manner.

Contraindications of Anamorelin (Adlumiz)

1. It is prohibited for patients who are allergic to any ingredients of this product.

2. It is contraindicated in patients with congestive heart failure [which may inhibit cardiac function and aggravate symptoms].

3. Patients with myocardial infarction or angina pectoris [the condition may worsen if heart function is suppressed and symptoms may worsen].

4. Patients with severe conduction disorders (such as complete atrioventricular block) [because this drug has the property of blocking sodium channels and has an inhibitory effect on the conduction system, it may aggravate the condition].

5. Patients receiving the following drugs: clarithromycin, itolaconazole, voriconazole, ritonavir-containing preparations, cobalt-containing bicistat preparations, and antirevir fumarate.

6. Patients with moderate or severe hepatic impairment (Child-Pugh class B and C) [Since the liver is the main factor in drug excretion from the body, blood drug concentration may increase, resulting in inhibition of the stimulation conduction system.

7. Patients who have difficulty taking oral food due to organic abnormalities of the gastrointestinal tract (such as gastrointestinal obstruction).

Recommended related articles: